S4 Fig 1: Astragaloside IV Effects on Peritoneal Fibrosis Signaling

Astragaloside IV treatment was associated with a significant attenuation of peritoneal fibrosis in a uremic rat model and human cell cultures. The 10.4 KB Excel dataset, authored by Tianxin Jiang and last updated in May 2026, likely contains experimental results from this study. Data indicates the antifibrotic effect may be mediated through the ENKUR/PI3K/Akt signaling pathway.

Use Cases

• Analyze the correlation between Astragaloside IV treatment and fibrosis marker levels based on the described in vivo and in vitro results.
• Model the ENKUR/PI3K/Akt signaling pathway activity based on the reported downregulation of pPI3K and pAkt.
• Investigate the relationship between extracellular matrix deposition and epithelial-mesenchymal transition markers like α-SMA and E-cadherin.
• Validate computational predictions of drug effects on high-glucose-induced peritoneal fibrosis using the experimental data.

Strengths

• Dataset is openly licensed under CC-BY-4.0, permitting reuse and redistribution.
• Specific biological markers and signaling pathways (ENKUR/PI3K/Akt, α-SMA, collagen IV, E-cadherin) are identified in the study description.
• Data originates from a controlled study using both in vivo (rat model) and in vitro (human cell) approaches.

Limitations

• Row count is unknown, which may limit suitability assessment for statistical analysis.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 10.4 KB, indicating limited scope.

Provenance

Source

figshare, authored by Tianxin Jiang.

Collection Method

Data likely gathered from laboratory experiments on uremic rat models and human peritoneal mesothelial cell cultures.

Freshness

Last updated 2026-05-08 17:38:45; freshness should be verified.